Ask AI
ProCE Banner Activity

Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer 

Slideset

In these downloadable slides, prostate cancer experts illustrate the best clinical practices for the application of available radioligand therapies used in metastatic castration-resistant prostate cancer, including the essential use of PSMA PET/CT for identifying eligible patients and evaluating response to PSMA-targeted radioligand therapy.

Released: September 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation